Literature DB >> 12661008

A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene.

Eva Maria Murga Penas1, Jan Cools, Petra Algenstaedt, Kristina Hinz, Doris Seeger, Philippe Schafhausen, Georgia Schilling, Peter Marynen, Dieter K Hossfeld, Judith Dierlamm.   

Abstract

The ETV6 gene is a member of the ETS family of transcription factors and the main target of chromosomal rearrangements affecting chromosome band 12p13. To date, more than 15 fusion partners of ETV6 have been characterized at the molecular level. Most of these fusions encode chimeric proteins with oncogenic properties. However, some of the translocations do not produce a functional fusion protein, but may induce ectopic expression of oncogenes located close to the breakpoint. We herein report the characterization and cloning of a novel cryptic translocation, t(12;17)(p13;p12-p13), occurring in a patient with an acute myeloid leukemia evolving from a chronic myelomonocytic leukemia. Cytogenetic analysis suggested the presence of a deletion of the short arm of chromosome 12, del(12)(p13), in three of the five metaphase cells analyzed. However, fluorescence in situ hybridization (FISH) with the ETV6-specific cosmid clones 179A6, 50F4, 163E7, and 148B6 as well as probes hybridizing to the TP53 gene on 17p13 and the subtelomeric region of 17p revealed the presence of a translocation between 12p and 17p. By FISH, the breakpoints could be localized in intron 1 of ETV6 and centromeric to TP53. By 3' rapid amplification of cDNA ends-polymerase chain reaction (3' RACE-PCR), a fusion transcript between exon 1 of ETV6 and the antisense strand of PER1 (period homolog 1, Drosophila), a circadian clock gene, could be identified. This ETV6-PER1 (antisense PER1 strand) fusion transcript does not produce a fusion protein, and no other fusion transcripts could be detected. We hypothesize that in the absence of a fusion protein, the inactivation of PER1 or deregulation of a gene in the neighborhood of PER1 may contribute to the pathogenesis of leukemias with a t(12;17)(p13;p12-p13). Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12661008     DOI: 10.1002/gcc.10175

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  9 in total

1.  Chimeric antisense RNA derived from chromosomal translocation modulates target gene expression.

Authors:  Takumi Sugimoto; Akihiro Tomita; Akihiro Abe; Chisako Iriyama; Hitoshi Kiyoi; Tomoki Naoe
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

Review 2.  Circadian rhythms and cancer.

Authors:  Sigal Gery; H Philip Koeffler
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

3.  RACK1, a novel hPER1-interacting protein.

Authors:  Lijuan Hu; Fang Lu; Yuhui Wang; Yanyou Liu; Desang Liu; Zhou Jiang; Chaomin Wan; Bin Zhu; Lu Gan; Yueqi Wang; Zhengrong Wang
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

4.  Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.

Authors:  Vijay P S Rawat; Monica Cusan; Aniruddha Deshpande; Wolfgang Hiddemann; Leticia Quintanilla-Martinez; R Keith Humphries; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-12       Impact factor: 11.205

5.  NCLscan: accurate identification of non-co-linear transcripts (fusion, trans-splicing and circular RNA) with a good balance between sensitivity and precision.

Authors:  Trees-Juen Chuang; Chan-Shuo Wu; Chia-Ying Chen; Li-Yuan Hung; Tai-Wei Chiang; Min-Yu Yang
Journal:  Nucleic Acids Res       Date:  2015-10-05       Impact factor: 16.971

6.  ChiTaRS 2.1--an improved database of the chimeric transcripts and RNA-seq data with novel sense-antisense chimeric RNA transcripts.

Authors:  Milana Frenkel-Morgenstern; Alessandro Gorohovski; Dunja Vucenovic; Lorena Maestre; Alfonso Valencia
Journal:  Nucleic Acids Res       Date:  2014-11-20       Impact factor: 16.971

7.  t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.

Authors:  Sarah B Mueller; Paola Dal Cin; Long P Le; Dora Dias-Santagata; Jochen K Lennerz; A John Iafrate; Hetal Desai Marble; Andrew M Brunner; Matthew J Weinstock; Marlise R Luskin; Daniel J De Angelo; Richard M Stone; Valentina Nardi
Journal:  Blood Adv       Date:  2022-01-08

8.  Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate.

Authors:  Ismail Siti Mariam; Ramli Norhidayah; Abu Bakar Zulaikha; Mohd Yunus Nazihah; Hassan Rosline; Ghazali Anis Kausar; Sulong Sarina; Husin Azlan; Ravindran Ankathil
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

9.  The Circadian Protein PER1 Modulates the Cellular Response to Anticancer Treatments.

Authors:  Marina Maria Bellet; Claudia Stincardini; Claudio Costantini; Marco Gargaro; Stefania Pieroni; Marilena Castelli; Danilo Piobbico; Paolo Sassone-Corsi; Maria Agnese Della-Fazia; Luigina Romani; Giuseppe Servillo
Journal:  Int J Mol Sci       Date:  2021-03-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.